Physician profile
Samir Mehta
NPI 1003851817
$3,646,148.72
in general payments reported to CMS, 2019-2025
43 companies · $754K in 2025
The $754K reported for 2025 was more than what 99% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279K · 2020: $428K · 2021: $401K · 2022: $498K · 2023: $587K · 2024: $700K · 2025: $754K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $1.6M · Consulting Fee: $173K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125K · Travel and Lodging: $78K · Honoraria: $63K · Food and Beverage: $9,614 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $1,589,776.27 |
| Consulting Fee | $172,779.81 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $124,533.43 |
| Travel and Lodging | $78,079.70 |
| Honoraria | $62,592.37 |
| Food and Beverage | $9,614.23 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,540.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $2,533,918.72 | 2019-2025 | Evos, Evos Mini, Trigen Intertan |
| Depuy Synthes Products, INC. | $506,310.07 | 2019-2025 | Expert Nail |
| Stryker Corporation | $177,511.83 | 2019-2025 | Axsos, Gamma, T2 Alpha |
| Globus Medical, INC. | $106,567.25 | 2019-2025 | Troch Nail, Autobahn, External Fixation |
| Medical Device Business Services, INC. | $78,643.17 | 2019-2025 | Va-Lcp, Tfn-Advance, Na |
| Curvafix, INC. | $74,687.96 | 2022-2025 | Curvafix Im Implant |
| Synthes USA Products LLC | $29,643.37 | 2019-2021 | |
| Amdt Holdings, INC. | $22,869.00 | 2020-2023 | Sixfix Circular Fixation System |
| Bioventus LLC | $21,771.77 | 2019-2025 | Exogen Ultrasound Bone Healing System |
| Arthrex, INC. | $20,673.00 | 2024-2025 | Amdt Mini-Rail, Sixfix Circular Fixation System |
| Biedermann Motech, INC. | $20,598.69 | 2019-2023 | Olecranon Plating System, Proximal Humerus Plating System, Distal Radius Plating System 2.0 |
| Synthes Gmbh | $17,062.23 | 2019-2025 | |
| Ucb Sa | $9,090.00 | 2021 | |
| Depuy Synthes Sales INC. | $4,729.93 | 2019-2025 | Va-Lcp, Lcp, Na |
| Davol INC. | $3,702.50 | 2022-2025 | Surgiphor |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$273,030.42 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.